Company to host conference call and webcast today at 8:00 a.m. EDT
Company to host conference call and webcast at 8:00 a.m. EDT
CARMIEL, Israel , Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization...
Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator ® platform to jointly develop pharmaceutical candidates for rare renal indications...
Company to host conference call and webcast today at 8:00 a.m. EST
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. (“Protalix” or “the...
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors...
New York, New York--(Newsfile Corp. - October 27, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Protalix BioTherapeutics, Inc. ("Protalix BioTherapeutics, Inc.")...
NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Protalix BioTherapeutics, Inc. ("Protalix" or the "Company") (NYSE: PLX). Such investors...